Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III trial investigating the efficacy of an encapsulated cell therapy product [NovaCaps] versus gemcitabine for advanced, inoperable pancreatic cancer

Trial Profile

Phase III trial investigating the efficacy of an encapsulated cell therapy product [NovaCaps] versus gemcitabine for advanced, inoperable pancreatic cancer

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 24 Oct 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Microencapsulated CYP2B1-expressing cells+ifosfamide PharmaCyte Biotech (Primary) ; Gemcitabine; Ifosfamide
  • Indications Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors PharmaCyte Biotech
  • Most Recent Events

    • 24 Oct 2016 According to a PharmaCyte Biotech media release, Manuel Hidalgo, MD, PhD has agreed to serve as the Principal Investigator for this trial.
    • 04 Nov 2013 Cloning of the cancer-drug-activating cells required for phase 3 clinical trials has begun at Inno Biologics, according to a Nuvilex media release.
    • 19 Sep 2013 Inno Biologics will generate cell clones for production of microencapsulated CYP-2B1-expressing cells for this trial, and Fisher BioServices will store them, according to a Nuvilex media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top